StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

by · The Cerbat Gem

Stock analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a report issued on Thursday. The firm set a “sell” rating on the stock.

Bio-Path Trading Up 11.9 %

Shares of Bio-Path stock opened at $0.18 on Thursday. The firm’s 50-day simple moving average is $0.36 and its 200-day simple moving average is $0.73. Bio-Path has a twelve month low of $0.12 and a twelve month high of $7.67.

Bio-Path Company Profile

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Articles